Edge Therapeutics, Inc. (EDGE) Reaches $0.96 1 Year Low; Southern First Bancshares, Inc. (SFST) Had 3 Bulls

May 21, 2018 - By Migdalia James

Edge Therapeutics, Inc. (NASDAQ:EDGE) Logo

The stock of Edge Therapeutics, Inc. (NASDAQ:EDGE) hit a new 52-week low and has $0.91 target or 5.00% below today’s $0.96 share price. The 8 months bearish chart indicates high risk for the $29.90 million company. The 1-year low was reported on May, 21 by Barchart.com. If the $0.91 price target is reached, the company will be worth $1.50M less. The stock decreased 2.05% or $0.02 during the last trading session, reaching $0.957. About 1.06M shares traded. Edge Therapeutics, Inc. (NASDAQ:EDGE) has risen 103.26% since May 21, 2017 and is uptrending. It has outperformed by 91.71% the S&P500.

Among 4 analysts covering Southern First Bancshares (NASDAQ:SFST), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Southern First Bancshares had 4 analyst reports since August 20, 2015 according to SRatingsIntel. As per Thursday, August 20, the company rating was maintained by Wood. Keefe Bruyette & Woods downgraded Southern First Bancshares, Inc. (NASDAQ:SFST) on Tuesday, November 29 to “Mkt Perform” rating. The rating was maintained by Sandler O’Neill on Thursday, January 25 with “Buy”. See Southern First Bancshares, Inc. (NASDAQ:SFST) latest ratings:

25/01/2018 Broker: Sandler O’Neill Rating: Buy New Target: $50.0 Maintain

More news for Edge Therapeutics, Inc. (NASDAQ:EDGE) were recently published by: Nasdaq.com, which released: “Edge Therapeutics Reports First Quarter 2018 Financial Results” on May 01, 2018. Nasdaq.com‘s article titled: “Edge Therapeutics Announces Review of Strategic Alternatives” and published on April 30, 2018 is yet another important article.

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital therapies for acute life-threatening neurological and other conditions. The company has market cap of $29.90 million. The Company’s lead product includes EG-1962, a polymer microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. It currently has negative earnings. The firm is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain.

Among 4 analysts covering Edge Therapeutics (NASDAQ:EDGE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Edge Therapeutics has $34 highest and $18 lowest target. $27.25’s average target is 2747.44% above currents $0.957 stock price. Edge Therapeutics had 5 analyst reports since October 26, 2015 according to SRatingsIntel. The rating was initiated by Guggenheim on Monday, October 26 with “Buy”. The firm has “Outperform” rating given on Monday, October 26 by Leerink Swann. The stock has “Outperform” rating by Credit Suisse on Monday, May 9. The firm earned “Market Outperform” rating on Monday, October 26 by JMP Securities. Credit Suisse initiated Edge Therapeutics, Inc. (NASDAQ:EDGE) on Monday, October 26 with “Outperform” rating.

The stock increased 0.42% or $0.2 during the last trading session, reaching $47.35. About 3,381 shares traded. Southern First Bancshares, Inc. (NASDAQ:SFST) has risen 37.12% since May 21, 2017 and is uptrending. It has outperformed by 25.57% the S&P500.

Southern First Bancshares, Inc. operates as the holding firm for Southern First Bank that provides various banking services and products to general public in South Carolina. The company has market cap of $349.52 million. It accepts various deposit products that include checking accounts, commercial checking accounts, savings accounts, and other time deposits. It has a 26.9 P/E ratio. The companyÂ’s loan portfolio comprises commercial real estate loans; construction real estate loans; commercial business loans for various lines of businesses, such as the manufacturing, service industry, and professional service areas; consumer real estate and home equity loans; and other consumer loans, including secured and unsecured installment loans and revolving lines of credit.

Since January 26, 2018, it had 0 insider buys, and 12 insider sales for $1.31 million activity. Strickland F Justin sold $20,418 worth of stock. $849 worth of Southern First Bancshares, Inc. (NASDAQ:SFST) was sold by CUBBAGE LEIGHTON M on Tuesday, May 8. Shares for $50,184 were sold by ELLEFSON ANNE S on Tuesday, May 1. Dowling Michael D sold $141,125 worth of Southern First Bancshares, Inc. (NASDAQ:SFST) on Thursday, May 10. SEAVER R ARTHUR JR sold 9,983 shares worth $468,194.

Investors sentiment decreased to 1.65 in 2017 Q4. Its down 0.23, from 1.88 in 2017Q3. It fall, as 4 investors sold Southern First Bancshares, Inc. shares while 16 reduced holdings. 8 funds opened positions while 25 raised stakes. 4.88 million shares or 0.30% less from 4.90 million shares in 2017Q3 were reported. First Advsr L P holds 0% or 14,823 shares in its portfolio. Geode Capital Mngmt Limited Liability Co owns 63,087 shares. Dimensional Fund Advisors Limited Partnership accumulated 0% or 175,925 shares. Vanguard Grp holds 287,655 shares. Northern Trust Corp reported 67,481 shares stake. New York-based Citigroup Inc has invested 0% in Southern First Bancshares, Inc. (NASDAQ:SFST). Livingston Group Inc Asset Mngmt (Operating As Southport Management) accumulated 0.1% or 6,587 shares. 21,315 are held by Bridgeway Mngmt. 8,592 are owned by State Common Retirement Fund. Royal Bancshares Of Canada invested 0% in Southern First Bancshares, Inc. (NASDAQ:SFST). Elizabeth Park Cap Advisors Limited invested 2.07% of its portfolio in Southern First Bancshares, Inc. (NASDAQ:SFST). Mendon Cap Advisors, New York-based fund reported 318,874 shares. Us Bank De accumulated 0% or 6,265 shares. Bnp Paribas Arbitrage holds 1,958 shares or 0% of its portfolio. Tower Lc (Trc) accumulated 47 shares.

Southern First Bancshares, Inc. (NASDAQ:SFST) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: